AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25264981
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment (10 mg/Kg/day)
Trial: 25264981
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and simultaneous exercise training
Trial: 25267381
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) for 6 months
Trial: 25267562
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (silicone metacarpophalangeal arthroplasty - SMPA)
Trial: 25267741
Drug: Glembatumumab vedotin
RxNorm normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glembatumumab vedotin (1.88 mg/kg every 3 weeks)
Trial: 25267741
Drug: Glembatumumab vedotin
RxNorm normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glembatumumab vedotin (1.5 mg/kg dosing during 2 of 3 weeks)
Trial: 25267741
Drug: Glembatumumab vedotin
RxNorm normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glembatumumab vedotin (1.0 mg/kg weekly)
Trial: 25267759
Drug: Post-transplantation cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplantation cyclophosphamide (PTCy) at 50 mg/kg/day on post-transplantation days +3 and +4
Trial: 25267955
Drug: Fecal calprotectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal calprotectin (FC) levels > 30 µg/g
Trial: 25267955
Drug: Combined test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined test using FC > 30µg/g and SIBDQ score < 6
Trial: 25270430
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (5 g/day: 1.9-2.2 g EPA; 1.1 g DHA)
Trial: 25270908
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (n = 121)
Trial: 25271871
Drug: Transcranial magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial magnetic stimulation (TMS) treatment
Trial: 25272081
Drug: Oka-RIT (Varilrix™)
RxNorm normalized name: ZOSTER VACCINE LIVE (OKA/MERCK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oka-RIT (Varilrix™) vaccine, 2 doses at 4.5 and 6.5 months post transplantation
Trial: 25272081
Drug: Oka-RIT (Varilrix™)
RxNorm normalized name: ZOSTER VACCINE LIVE (OKA/MERCK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oka-RIT (Varilrix™) vaccine
Trial: 25273351
Drug: C-reactive protein,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-BNP, cardiac troponin T
Trial: 25273351
Drug: A score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A score combining 5 biomarkers (C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-BNP, cardiac troponin T)
Trial: 25274394
Drug: Augmentation Pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation Pressure (AP)
Trial: 25274394
Drug: Heart Rate-Adjusted
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart Rate-Adjusted Augmentation Index (AI75)
Trial: 25276415
Drug: Clonidine (4 µg/kg)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (4 µg/kg)
Trial: 25276665
Drug: Darunavir (Prezista(®))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir (Prezista(®)) with low-dose ritonavir (DRV/r) 600/100 mg twice daily
Trial: 25280062
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) enoxaparin at a standard dose of 1 mg/kg every 12 h
Trial: 25281031
Drug: Copper histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Copper histidine treatment (early treatment prior to onset of symptoms)
Trial: 25281041
Drug: Old formulation
RxNorm normalized name: Poly Hist PD (old formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old formulation of UFH
Trial: 25281041
Drug: New formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation of UFH
Trial: 25281041
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations of UFH
Trial: 25281400
Drug: Rifabutin dosed
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin dosed at 5 mg/kg three times a week
Trial: 25283266
Drug: Axitinib at
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib at a starting dose of 5 mg b.i.d.
Trial: 25284275
Drug: Adalimumab retreatment
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab retreatment (80 mg initial dose, followed by 40 mg every-other-week for 16 weeks)
Trial: 25285126
Drug: MenACYW-D (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACYW-D (two doses at 12 and 18 months)
Trial: 25285126
Drug: Meningococcal serogroup
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal serogroup C conjugate vaccine (MCC, one dose at 12 months)
Trial: 25285126
Drug: DTaP-IPV-Hib (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-Hib (administered concomitantly with MenACYW-D)
Trial: 25285269
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with tiotropium for newly diagnosed COPD patients
Trial: 25285572
Drug: No protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No protease inhibitors (Control)
Trial: 25286053
Drug: Rapamycin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapamycin treatment before the first islet infusion; induction therapy with anti-thymocyte globulin (ATG); short-term treatment with steroids and interleukin-1Ra; maintenance therapy with rapamycin+mycophenolate mofetil
Trial: 25286053
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with anti-thymocyte globulin (ATG)
Trial: 25286173
Drug: β-lactam and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactam and macrolide combination treatment
Trial: 25287822
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg per day plus capecitabine 1,500 mg/m2 per day
Trial: 25288018
Drug: Weekly rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly rituximab consolidation (375 mg/m², four times infusion) after four cycles of R-CHOP21
Trial: 25289522
Drug: Oseltamivir, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir, single 75 mg dose administered before APD treatment.
Trial: 25290090
Drug: Bosutinib 300
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 300 mg once daily plus capecitabine 1000 mg m(-2) twice daily
Trial: 25293768
Drug: Rituximab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (4 infusions of 375 mg/m²)
Trial: 25293768
Drug: Rituximab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (2 fixed 1-g infusions 2 weeks apart)
Trial: 25293773
Drug: Local radiotherapy
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local radiotherapy to solitary lymphoma nodes and intranodal injections of low-dose rituximab (5 mg), immature autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor, repeated 3 times targeting different lymphoma nodes
Trial: 25294897
Drug: Refametinib plus
RxNorm normalized name: Refametinib
DrugBank: Refametinib (DB06309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refametinib plus sorafenib (refametinib 50 mg twice daily, sorafenib 200 mg morning/400 mg evening, with possible escalation to 400 mg twice daily from cycle 2)
Trial: 25295432
Drug: Antipsychotic-treated patients
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic-treated patients
Trial: 25295646
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine (LDX) up to 70 mg/day for 5 weeks
Trial: 25295646
Drug: Mixed amphetamine
RxNorm normalized name: mixed amphetamine salts 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts-immediate release (MAS-IR) up to 45 mg/day for 5 weeks
Trial: 25296762
Drug: Moderate-SFA reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-SFA reduction (3.68-13.67 g)
Trial: 25296762
Drug: High-SFA reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-SFA reduction (>13.67 g)
Trial: 25296762
Drug: Low-SFA reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-SFA reduction (<3.68 g)
Trial: 25299251
Drug: Best treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best treatment options for dengue patients with refractory shock
Trial: 25303490
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human chorionic gonadotropin (r-hCG) 25 μg iv administration
Trial: 25304641
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg daily and ribavirin starting at 400 mg daily (adjusted according to creatinine clearance and hemoglobin values) for 24 weeks
Trial: 25304729
Drug: IFN-α therapy
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α therapy (3 MU 3 times weekly)
Trial: 25304853
Drug: Early aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early aspirin therapy
Trial: 25305705
Drug: ACE inhibitor/angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor/angiotensin receptor blocker (ACEI/ARB)
Trial: 25305705
Drug: Antihypertensive agent
RxNorm normalized name: Antihypertensive agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive agent not affecting the renin angiotensin system (non-RAS)
Trial: 25307711
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 5 ml/kg of Ringer's acetate intravenously for over 15 min
Trial: 25308138
Drug: h-FABP above
FDA approved: no
EMA approved: no
PMDA approved: no
Description: h-FABP above 6 μg/L
Trial: 25308138
Drug: BNP >
RxNorm normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP > 100 pg/mL
Trial: 25308138
Drug: cTnI-Ultra >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cTnI-Ultra > 0.05 μg/L
Trial: 25308138
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of h-FABP with PESI
Trial: 25309090
Drug: Sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium phosphate (NaP) tablets, 4 tablets with 250 mL of water every 15 min, three times on the day of the procedure.
Trial: 25312446
Drug: Antipsychotic polytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic polytherapy
Trial: 25313095
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg every 2 weeks (with dose adjustments for weight)
Trial: 25313914
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg recombinant-human chorionic gonadotropin
Trial: 25314069
Drug: α-tocopherol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-tocopherol (50 mg/day)
Trial: 25314069
Drug: β-carotene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-carotene (20 mg/day)
Trial: 25314291
Drug: CC-carriers (n=20)
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-carriers (n=20)
Trial: 25318437
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg IV on Days 1, 8, 15, and 22 of a 28 day cycle and Bevacizumab 10 mg/kg IV on Days 1 and 15 of the cycle
Trial: 25320340
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (1000 mg/once daily) with prednisolone (5 mg/twice daily)
Trial: 25320355
Drug: Ridaforolimus (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus (10-40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week)
Trial: 25320355
Drug: Ridaforolimus and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus and dalotuzumab combination
Trial: 25322359
Drug: Frozen fecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen fecal microbiota transplantation (FMT) capsules, 15 capsules administered on 2 consecutive days.
Trial: 25323764
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (r-hGH) therapy at a mean dose of 0.053 mg/kg/day over 3 years
Trial: 25324973
Drug: 350 ng
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 ng aviscumine twice weekly by subcutaneous injection until progression
Trial: 25327505
Drug: Amikacin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (20 mg/kg)
Trial: 25327505
Drug: Amikacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (25 mg/kg)
Trial: 25328681
Drug: PROSTVAC immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROSTVAC immunotherapy
Trial: 25328711
Drug: Melatonin 6mg
RxNorm normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 6mg oral for 3 months
Trial: 25329562
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid 25 mg daily for 2 weeks
Trial: 25329821
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1200 mg as carbonate)
Trial: 25330463
Drug: liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.2 mg QD sc for 12 weeks
Trial: 25331113
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m² plus liposomal doxorubicin 20 mg/m² (R-Dox) every 3 weeks
Trial: 25331616
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m2, intravenous, twice a week for 2 weeks, maximum of 8 cycles)
Trial: 25332326
Drug: [(13)C5]5-formyltetrahydrofolate delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [(13)C5]5-formyltetrahydrofolate delivered in a pH-sensitive enteric caplet (855 nmol / 400 μg)
Trial: 25332326
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of [(13)C5]5-formyltetrahydrofolate (214 nmol)
Trial: 25332483
Drug: 54 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54 g/d LNS with milk protein base (milk-LNS)
Trial: 25332483
Drug: 54 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 54 g/d LNS with soy protein base (soy-LNS)
Trial: 25332483
Drug: 71 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 71 g/d corn-soy blend (CSB)
Trial: 25335932
Drug: OSI-906 50
RxNorm normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSI-906 50 mg BID; everolimus 5 mg QD
Trial: 25335932
Drug: OSI-906 100
RxNorm normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSI-906 100 mg BID; everolimus 10 mg QD
Trial: 25335932
Drug: OSI-906 100
RxNorm normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSI-906 100 mg BID; everolimus 5 mg QD
Trial: 25336464
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg IV infusion at baseline and on day 15)
Trial: 25338318
Drug: Nintedanib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (oral, small-molecule tyrosine kinase inhibitor)
Trial: 25338926
Drug: FPG ≥5.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG ≥5.6 mmol/L
Trial: 25338926
Drug: FPG combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG combined with A1C (FPG ≥5.6 mmol/L and/or A1C ≥5.7% [39 mmol/mol])
Trial: 25340593
Drug: poly-L-lactic acid
RxNorm normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: poly-L-lactic acid
Trial: 25340778
Drug: Combined antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antiretroviral therapy (cART) for 8 months
Trial: 25340784
Drug: GLP-1 agonist
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 agonist therapy
Trial: 25342141
Drug: MEDI-573 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-573 (5 mg/kg, 15 mg/kg, 45 mg/kg on Day 1, 8, and 15 of 21-day cycles)
Trial: 25343737
Drug: Interview survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interview survey tool about bullying administered to children
Trial: 25344362
Drug: Trametinib and
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib and everolimus (daily dosing with both agents)
Trial: 25344362
Drug: Trametinib and
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib and everolimus (daily dosing with trametinib and intermittent everolimus dosing)
Trial: 25344536
Drug: Prolonged continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged continuous positive airway pressure (CPAP) therapy with supplemental oxygen
Trial: 25347448
Drug: Oral anti-psychotic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anti-psychotic therapy (retrospective)
Trial: 25348520
Drug: Faldaprevir (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir (480 mg)
Trial: 25348609
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg elemental zinc, oral zinc acetate, twice daily for 14 days)
Trial: 25349968
Drug: Pazopanib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (oral angiogenesis inhibitor targeting VEGFR/PDGFR/c-Kit)
Trial: 25351198
Drug: IK-5001 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IK-5001 (2 ml of 1% sodium alginate plus 0.3% calcium gluconate) administered by selective injection through the infarct-related coronary artery within 7 days after myocardial infarction
Trial: 25352936
Drug: Efavirenz monotherapy
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz monotherapy (600 mg single dose and 600 mg/d for 17 days)
Trial: 25355245
Drug: Oral lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral lenalidomide at a dose of 25 mg daily on days 1 to 21 of each 28-day cycle
Trial: 25355284
Drug: 160-mg subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160-mg subcutaneous ixekizumab injection at Week 0, 80-mg every 2 weeks through Week 12 and 80-mg every 4 weeks through Week 24
Trial: 25355819
Drug: Ibrutinib (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (280 or 560 mg) combined with rituximab (375 mg/m(2)) and bendamustine (90 mg/m(2))
Trial: 25355844
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg efavirenz daily
Trial: 25357043
Drug: AeroForm patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AeroForm patient-controlled tissue expanders; 10-cc dose of carbon dioxide gas administered three times daily with a 3-hour lockout until full expansion achieved.
Trial: 25358826
Drug: Phosphodiesterase type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase type 5 inhibitors (PDE5i)
Trial: 25358826
Drug: Weekly use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly use of PDE5i